Global Coronary Stents Market Outlook, 2007 - 2020
|出版商||ABMRG (Ace Business and Market research Group)||商品編碼||307540|
|出版日期||內容資訊||英文 545 Pages
The global coronary stent market is expected grow, despite the current downward trend in the US, the largest market, and declining selling prices globally.
The market study takes into account various global clinical studies and pipeline products and it suggests that the coronary stent pipeline is clustered with new generation Drug Eluting Stent (DES), bioactive stents, bioabsorbable technology and stents for the niche segments such as complex and bifurcated vessels. Altering the trend, small to medium size companies from the developing economies are ambitiously conducting clinical studies to win the approvals and expand the use of devices for new indications.
The stent market globally and in the developed nations is largely controlled by three players-Abbott Laboratories, Boston Scientific, and Medtronic. While in developing economies, small and medium players from Asia and Europe have a considerable share in terms of volume.
This comprehensive, 465 page global strategic business report is authored by team of sector analysts who used rigorous primary and secondary research, robust analytical model to provide strategic insight and to forecast in for all major stent types BMS, DES, Bioabsorbable stents in leading 23 geographies.
It provides data at global, continents, economic zones, and country level
Market size of coronary stents in terms - value and volume (2007-2020) for BMS, DES and Bioabsorbables (Bioresorbable - BVS)
Market growth rates (2007-2020)
Average prices of various stents in all the covered geographies (2007-2020)
Number of PCI procedures
Analytical comparison between different continents and economic regions
Market dynamics - market trends, drivers, restrains, issues, competitive landscape
Detailed pipeline and clinical studies
Product approval status - major geographies
Industry consolidation, partnerships, product launches, approvals and recalls
Detailed company profiles of around 70 companies from different levels of value chain
Market expansion and market entry strategy
Product, production and inventory planning
Management and investors presentations
Due diligence to identify targets for M&A
Identifying in-licensing and out-licensing partners
Tracking present and future competition
Venture capitalists, Investment banks, Angel investors
Governments, trade and commerce organizations
Wide coverage of geographies
Companies from various levels of value chain
Detailed presentation of pipeline and clinical studies
Projections based on detailed and rigorous primary research to validate optimistic and pessimistic approach
Used advanced computational, robust statistical and analytical models
Considered mid and late stage assets